circRNA basic information
circBase ID: hsa_circ_0000620
Name: hsa_circ_AAGAB
Synonym: circAAGAB
Host Gene: AAGAB
Genomic location(hg19): chr15:67524151-67529158:-
Genomic location(hg38): chr15:67231813-67236820:-
Subcellular localization: cytoplasm
 
 
 
 
 
 
 
Disease basic information
MONDO ID:
0005580
MONDO name: esophageal squamous cell carcinoma
Disease details: esophageal squamous cell carcinoma
Disease DO ID:
3748
Disease MeSH ID:
C562729; D000077277
Disease NCIt ID:
C4024
Disease ICD11 ID:
1417891145
Disease OMIM ID:
-
Species: Human
Species details: Homo sapiens
Tissue specimen:

ESCC tissues; matched adjacent normal tissues; blood samples; plasma samples; tumor tissues

Cell lines:

KYSE150; TE1

In vivo animal model:

cell line-derived xenograft; patient-derived xenograft

circRNA-disease information
Expression pattern:
DN
Associated gene: GAS7c, Sam68, PABP1, TNFAIP2 mRNA, TNFAIP2, Rac1, ZNF460
Associated microRNA: miR-671-5p
Biological function: circAAGAB acts as a tumor-suppressive regulator in ESCC, suppressing ESCC cell proliferation, clonogenicity, migration, invasion, tumor growth, and metastasis.
Molecular mechanism: S. mitis-secreted MLY induces ZNF460 degradation and represses circAAGAB transcription; circAAGAB suppresses ESCC through miR-671-5p/GAS7c/Sam68-mediated inhibition of PI3K/AKT/GSK-3beta signaling and through binding PABP1 to destabilize TNFAIP2 mRNA and inhibit Rac1/ERK/STAT3 signaling.
Biological pathway or process:

PI3K/AKT (inhibits); ERK (inhibits); proliferation (inhibits); migration (inhibits); invasion (inhibits); metastasis (inhibits); EMT (inhibits); ceRNA regulation (promotes); mRNA stability (inhibits); other pathway/process (inhibits)

Detected method:
Q
S
Validation methods:

Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RT-qPCR; RNA-seq; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Co-IP; ChIP / ChIP-seq; Luciferase Reporter Assay; Transfection; Colony Formation Assay; Transwell Assay; In Vivo Animal Model; H&E Staining; IHC (Immunohistochemistry); Western Blot; Cohort Study; Survival Analysis; Bioinformatics Analysis

Clinical significance:

Reduced circAAGAB expression correlated with advanced TNM staging and predicted shorter disease-free survival; circAAGAB was reduced in ESCC tissues and patient plasma, indicating potential prognostic biomarker value.

Description:

circAAGAB is a human AAGAB-derived circRNA that is downregulated in ESCC tissues and patient blood/plasma, and low expression is associated with advanced TNM stage and shorter disease-free survival. It functions as a tumor suppressor by inhibiting ESCC proliferation, clonogenicity, migration, invasion, and tumor progression. Mechanistically, S. mitis-secreted MLY promotes ZNF460 proteasomal degradation to repress circAAGAB, while circAAGAB suppresses oncogenic signaling through the miR-671-5p/GAS7c/Sam68 and PABP1/TNFAIP2/Rac1 axes.

Confidence score:

0.8966

Other information
Title:

Targeting intratumoral Streptococcus mitis suppresses the progression of esophageal squamous cell carcinoma.

Journal: Science China. Life sciences
Published: 2026
PubMed ID: 41587007
Study type:

combined biological and clinical study

Data availability: PRJCA030742; https://doi.org/10.1007/s11427-025-3097-2
Code availability: -